Liver-function tests in children and adolescents on antipsychotics: a one-year follow-up study

2016 ◽  
Author(s):  
Inmaculada Baeza Pertegaz
Keyword(s):  
Liver Function ◽  
Children And Adolescents ◽  
Liver Function Tests ◽  
Follow Up Study ◽  
Function Tests ◽  
One Year

Liver-function tests in children and adolescents on antipsychotics: a one-year follow-up study

2016 ◽  
Vol 26 ◽  
pp. S734-S735
Author(s):  
I. Baeza Pertegaz ◽  
E. De la Serna ◽  
R. Calvo-Escalona ◽  
A. Morer ◽  
J. Merchán-Naranjo ◽  
...  
Keyword(s):  
Liver Function ◽  
Children And Adolescents ◽  
Liver Function Tests ◽  
Follow Up Study ◽  
Function Tests ◽  
One Year

Liver function tests and one year risperidone treatment in children and adolescents

2011 ◽  
Vol 26 (S2) ◽  
pp. 280-280
Author(s):  
A. Erdogan ◽  
N. Yurteri ◽  
A.E. Tufan ◽  
H. Ankarali ◽  
E. Demirci
Keyword(s):  
Liver Function ◽  
Children And Adolescents ◽  
Liver Enzymes ◽  
Antipsychotic Agent ◽  
Liver Function Tests ◽  
Function Tests ◽  
The Mean ◽  
One Year ◽  
Risperidone Treatment

ObjectiveRisperidone is an atypical antipsychotic agent, despite its many advantages and widespread use, there is increasing attention to the adverse effects associated with long-term exposure to this drug.We aimed to investigate the changes in the liver function tests (LFTs) associated with one year risperidone treatment in children and adolescents.MethodsOne hundred youths who treated with risperidone more than one year were included in the study. For this study, patients’ baseline and follow-up weight and hepatobiliary function tests including alanine aminotransferases(ALT) and aspartat aminotransferases (AST), gamma gluatamyl transerase (GGT), alkaline phosphatase (ALP) and serum bilirubin levels were measured baseline, after the treatment period of six months and one year.ResultsAsymptomatic liver function test abnormalities mostly ALP elevation was found in subjects treated with risperidone. The mean levels of liver enzymes and billuribin of the patients were significantly higher after one year of treatment than the baseline. Also the mean levels of liver enzymes and billuribin of the patients were significantly higher after one year of treatment than the six months. There was significant association between changes in weight, risperidone dose and liver enzymes and billuribin levels.ConclusionsThese findings suggest that risperidone treatment in the long term commonly leads to liver function changes however it rarely may induce a serious hepatic toxicity at therapeutic doses in children and adolescents.

A follow-up study of liver function tests after surgical treatment for gallstone diseases

1977 ◽  
Vol 12 (6) ◽  
pp. 446-454
Author(s):  
Takashi Harada ◽  
Hitoshi Sugaya ◽  
Misao Maehara ◽  
Kazuo Kimura ◽  
Tohru Hisauchi ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Liver Function ◽  
Liver Function Tests ◽  
Follow Up Study ◽  
Function Tests

scholarly journals Abnormal Liver Function Tests and Long-Term Outcomes in Patients Discharged after Acute Heart Failure

2021 ◽  
Vol 10 (8) ◽  
pp. 1730
Author(s):  
Hiroshi Miyama ◽  
Yasuyuki Shiraishi ◽  
Shun Kohsaka ◽  
Ayumi Goda ◽  
Yosuke Nishihata ◽  
...  
Keyword(s):  
Heart Failure ◽  
Liver Function ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Adverse Outcomes ◽  
Long Term Outcomes ◽  
Function Tests ◽  
Parameter Values

Abnormal liver function tests (LFTs) are known to be associated with impaired clinical outcomes in heart failure (HF) patients. However, this implication varies with each single LFT panel. We aim to evaluate the long-term outcomes of acute HF (AHF) patients by assessing multiple LFT panels in combination. From a prospective multicenter registry in Japan, 1158 AHF patients who were successfully discharged were analyzed (mean age, 73.9 ± 13.5 years; men, 58%). LFTs (i.e., total bilirubin, aspartate aminotransferase or alanine aminotransferase, and alkaline phosphatase) at discharge were assessed; borderline and abnormal LFTs were defined as 1 and ≥2 parameter values above the normal range, respectively. The primary endpoint was composite of all-cause death or HF readmission. At the time of discharge, 28.7% and 8.6% of patients showed borderline and abnormal LFTs, respectively. There were 196 (16.9%) deaths and 298 (25.7%) HF readmissions during a median 12.4-month follow-up period. The abnormal LFTs group had a significantly higher risk of experiencing the composite outcome (adjusted hazard ratio: 1.51, 95% confidence interval: 1.08–2.12, p = 0.017), whereas the borderline LFTs group was not associated with higher risk of adverse events when referenced to the normal LFTs group. Among AHF patients, the combined elevation of ≥2 LFT panels at discharge was associated with long-term adverse outcomes.

scholarly journals Cystic fibrosis-related liver disease: a single-center experience

2011 ◽  
Vol 3 (3) ◽  
pp. 21 ◽  
Author(s):  
Paula Catarino Costa ◽  
Celeste Canha Barreto ◽  
Luisa Pereira ◽  
Maria Luisa Lobo ◽  
Maria Adília Costa ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Liver Disease ◽  
Liver Function ◽  
Pediatric Patients ◽  
Liver Function Tests ◽  
Liver Involvement ◽  
Clinical Expression ◽  
Function Tests ◽  
Related Liver Disease

Prospective studies concerning liver disease in pediatric cystic fibrosis patients are scarce. The present study aimed to describe the prevalence and clinical expression of cystic fibrosis - related liver disease, in a cohort of 62 pediatric patients. Descriptive study, resulting from the prospective evaluation, between 1994 and 2009, of 62 pediatric patients (age <18 years) with cystic fibrosis. The follow-up protocol included a clinical assessment every 2 months, liver function tests every 6 months and annual liver ultrasonography. The cumulative prevalence of liver disease was 11.2% (7/62 cases). All patients had ΔF508 mutation and pancreatic insufficiency, none had meconium ileus. The liver involvement became clinically evident at a mean age of 8 years (3-15 years), revealed by hepatomegaly or hepatosplenomegaly (3 cases) and/ or abnormalities of liver function tests (3 cases) changes of liver ultrasound (7 cases) with evidence of portal hypertension (2 cases). Four patients were submitted to liver biopsy; biliary fibrosis was documented in one case, focal biliary cirrhosis in 2 cases and multilobular cirrhosis in another case. Within a median 11.6 years follow-up period (all patients under UDCA therapy after liver disease diagnosis), progression of liver disease was observed in 2 patients; one patient developed refractory variceal bleeding and progressive hepatic failure, requiring liver transplant. The results of the present study agree with those of previous pediatric studies, further documenting clinical expression of liver disease in CF patients, which is usually detected in the first decade of life and emphasize the contribution of ultrasound to early diagnosis of liver involvement. Moreover, although advanced liver disease is a relatively rare event, early isolated liver transplantation may have to be considered at this age group.

Risperidone and liver function tests in children and adolescents: A short-term prospective study

2008 ◽  
Vol 32 (3) ◽  
pp. 849-857 ◽  
Author(s):  
Ayten Erdogan ◽  
Nuray Atasoy ◽  
Hanife Akkurt ◽  
Devrim Ozturk ◽  
Elif Karaahmet ◽  
...  
Keyword(s):  
Liver Function ◽  
Prospective Study ◽  
Children And Adolescents ◽  
Liver Function Tests ◽  
Short Term ◽  
Function Tests
Sign in / Sign up

Export Citation Format

Share Document